Literature DB >> 17917030

Innovative BMT methods for intractable diseases.

Susumu Ikehara1.   

Abstract

We have recently established new bone marrow transplantation (BMT) methods for the treatment of intractable diseases. The methods include the perfusion method (PM) for the collection of bone marrow cells, and intra-bone marrow (IBM)-BMT for the direct injection of collected whole bone marrow cells into the bone marrow cavity. The PM, in comparison with the conventional aspiration method, can minimize the contamination of bone marrow cells (BMCs) with T cells from the peripheral blood. Therefore, without removing T cells, no graft-versus-host disease (GvHD) develops in the case of the PM. Since BMCs collected by the PM contain not only hemopoietic stem cells (HSCs) but also mesenchymal stem cells (MSCs), the injection of both cells directly into the bone marrow cavity (IBM-BMT) facilitates the engraftment of donor hemopoietic cells. In organ allografts with IBM-BMT, no graft failure occurs even if the radiation dose is reduced. In addition, IBM-BMT is applicable to regeneration therapy and various age-associated diseases such as osteoporosis, since it can efficiently recruit donor-derived normal MSCs. Finally, we show that IBM-BMT in conjunction with donor lymphocyte infusion (DLI) can prevent GvHD but suppress tumor growth. We believe that this strategy heralds a revolution in the field of transplantation (BMT and organ allografts) and regeneration therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17917030     DOI: 10.1007/s12026-007-0004-4

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  37 in total

1.  High marrow seeding efficiency of human lymphomyeloid repopulating cells in irradiated NOD/SCID mice.

Authors:  J D Cashman; C J Eaves
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice.

Authors:  A Peled; O Kollet; T Ponomaryov; I Petit; S Franitza; V Grabovsky; M M Slav; A Nagler; O Lider; R Alon; D Zipori; T Lapidot
Journal:  Blood       Date:  2000-06-01       Impact factor: 22.113

Review 3.  Stem cell homing: rolling, crawling, and nesting.

Authors:  P J Quesenberry; P S Becker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.

Authors:  P Hentschke; L Barkholt; M Uzunel; J Mattsson; P Wersäll; P Pisa; J Martola; N Albiin; A Wernerson; M Söderberg; M Remberger; A Thörne; O Ringdén
Journal:  Bone Marrow Transplant       Date:  2003-02       Impact factor: 5.483

5.  Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus.

Authors:  P G Beatty; C Anasetti; J A Hansen; G M Longton; J E Sanders; P J Martin; E M Mickelson; S Y Choo; E W Petersdorf; M S Pepe
Journal:  Blood       Date:  1993-01-01       Impact factor: 22.113

6.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.

Authors:  P L Weiden; N Flournoy; E D Thomas; R Prentice; A Fefer; C D Buckner; R Storb
Journal:  N Engl J Med       Date:  1979-05-10       Impact factor: 91.245

7.  Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/severe combined immune deficiency mice: implications for stem cell frequency assessment.

Authors:  P B van Hennik; A E de Koning; R E Ploemacher
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

8.  Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.

Authors:  Brian I Rini; Todd Zimmerman; Walter M Stadler; Thomas F Gajewski; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

Review 9.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells.

Authors:  Tsvee Lapidot; Isabelle Petit
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

Review 10.  Autoimmune diseases as stem cell disorders: normal stem cell transplant for their treatment (Review).

Authors:  S Ikehara
Journal:  Int J Mol Med       Date:  1998-01       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.